Literature DB >> 27662102

The CF gastrointestinal microbiome: Structure and clinical impact.

Geraint B Rogers1, Michael R Narkewicz2,3, Lucas R Hoffman4,5.   

Abstract

The gastrointestinal (GI) microbiome is shaped by host diet, immunity, and other physicochemical characteristics of the GI tract, and perturbations such as antibiotic treatments can lead to persistent changes in microbial constituency and function. These GI microbes also play critical roles in host nutrition and health. A growing body of evidence suggests that the GI microbiome in people with CF is altered, and that these dysbioses contribute to disease manifestations in many organs, both within and beyond the GI tract. Therapies that people with CF receive, even those targeting the respiratory tract, may impact the CF GI microbiome in ways that can influence the outcome of treatment. These new perspectives on the microbial contents of the CF intestine offer new opportunities for preventing a variety of CF-associated disorders. Pediatr Pulmonol. 2016;51:S35-S44.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  antibiotic therapy; cystic fibrosis (CF); gastrointestinal; microbiome

Year:  2016        PMID: 27662102      PMCID: PMC5303757          DOI: 10.1002/ppul.23544

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  99 in total

Review 1.  The gut flora as a forgotten organ.

Authors:  Ann M O'Hara; Fergus Shanahan
Journal:  EMBO Rep       Date:  2006-07       Impact factor: 8.807

2.  Microbiota signalling through MyD88 is necessary for a systemic neutrophilic inflammatory response.

Authors:  Dipti Karmarkar; Kenneth L Rock
Journal:  Immunology       Date:  2013-12       Impact factor: 7.397

Review 3.  Potential role of the intestinal microbiota in programming health and disease.

Authors:  Olivier Goulet
Journal:  Nutr Rev       Date:  2015-08       Impact factor: 7.110

4.  Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota.

Authors:  Amanda F Goddard; Benjamin J Staudinger; Scot E Dowd; Amruta Joshi-Datar; Randall D Wolcott; Moira L Aitken; Corinne L Fligner; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

5.  Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function.

Authors:  Caleb J Kelly; Leon Zheng; Eric L Campbell; Bejan Saeedi; Carsten C Scholz; Amanda J Bayless; Kelly E Wilson; Louise E Glover; Douglas J Kominsky; Aaron Magnuson; Tiffany L Weir; Stefan F Ehrentraut; Christina Pickel; Kristine A Kuhn; Jordi M Lanis; Vu Nguyen; Cormac T Taylor; Sean P Colgan
Journal:  Cell Host Microbe       Date:  2015-04-09       Impact factor: 21.023

6.  Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns.

Authors:  Maria G Dominguez-Bello; Elizabeth K Costello; Monica Contreras; Magda Magris; Glida Hidalgo; Noah Fierer; Rob Knight
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

Review 7.  Intestinal microbiology in early life: specific prebiotics can have similar functionalities as human-milk oligosaccharides.

Authors:  Raish Oozeer; Kees van Limpt; Thomas Ludwig; Kaouther Ben Amor; Rocio Martin; Richèle D Wind; Günther Boehm; Jan Knol
Journal:  Am J Clin Nutr       Date:  2013-07-03       Impact factor: 7.045

Review 8.  Neonatal Gastrointestinal and Respiratory Microbiome in Cystic Fibrosis: Potential Interactions and Implications for Systemic Health.

Authors:  Juliette C Madan
Journal:  Clin Ther       Date:  2016-03-10       Impact factor: 3.393

9.  Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis.

Authors:  Thomas Flass; Suhong Tong; Daniel N Frank; Brandie D Wagner; Charles E Robertson; Cassandra Vogel Kotter; Ronald J Sokol; Edith Zemanick; Frank Accurso; Edward J Hoffenberg; Michael R Narkewicz
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

Review 10.  Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences.

Authors:  Matteo Serino; Vincent Blasco-Baque; Simon Nicolas; Remy Burcelin
Journal:  Curr Cardiol Rep       Date:  2014-11       Impact factor: 2.931

View more
  7 in total

1.  A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders.

Authors:  Bu'Hussain Hayee; Kerry-Lee Watson; Sanchika Campbell; Anna Simpson; Emma Farrell; Penelope Hutchings; Patricia Macedo; Felicity Perrin; Kevin Whelan; Caroline Elston
Journal:  United European Gastroenterol J       Date:  2019-08       Impact factor: 4.623

2.  Altered Stool Microbiota of Infants with Cystic Fibrosis Shows a Reduction in Genera Associated with Immune Programming from Birth.

Authors:  Katherine M Antosca; Diana A Chernikova; Courtney E Price; Kathryn L Ruoff; Kewei Li; Margaret F Guill; Natalie R Sontag; Hilary G Morrison; Shuyu Hao; Mitchell L Drumm; Todd A MacKenzie; Dana B Dorman; Lynn M Feenan; Molly A Williams; John Dessaint; Irene H Yuan; Brian J Aldrich; Lisa A Moulton; Lily Ting; Ana Martinez-Del Campo; Edward J Stewart; Margaret R Karagas; George A O'Toole; Juliette C Madan
Journal:  J Bacteriol       Date:  2019-07-24       Impact factor: 3.490

3.  Correlation of Gut Microbiota, Vitamin D Status, and Pulmonary Function Tests in Children With Cystic Fibrosis.

Authors:  Hadeel Albedewi; Iman Bindayel; Ahmed Albarrag; Hanaa Banjar
Journal:  Front Nutr       Date:  2022-06-09

4.  Probiotics for people with cystic fibrosis.

Authors:  Michael J Coffey; Millie Garg; Nusrat Homaira; Adam Jaffe; Chee Y Ooi
Journal:  Cochrane Database Syst Rev       Date:  2020-01-22

Review 5.  Probiotics in Medicine: A Long Debate.

Authors:  Elisavet Stavropoulou; Eugenia Bezirtzoglou
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

6.  Changes in fecal microbiota with CFTR modulator therapy: A pilot study.

Authors:  C E Pope; A T Vo; H S Hayden; E J Weiss; S Durfey; S McNamara; A Ratjen; B Grogan; S Carter; L Nay; M R Parsek; P K Singh; E F McKone; M L Aitken; M R Rosenfeld; L R Hoffman
Journal:  J Cyst Fibros       Date:  2020-12-31       Impact factor: 5.527

Review 7.  The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases.

Authors:  Dapeng Zhang; Sha Li; Ning Wang; Hor-Yue Tan; Zhimin Zhang; Yibin Feng
Journal:  Front Microbiol       Date:  2020-02-25       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.